Engineering Subcutaneous Ectopic Tertiary Lymphoid Structures as Personalized Immune-Activation Niches for Cancer Immunotherapy
ACS Applied Bio Materials · 02.11.2026 · 9 (21) · 10525-10535
DOI: 10.1021/acsabm.6c01731 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, online erschienen am 20.10.2026. Verfasst von Jing-Yun Su und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing…. Hauptthemen laut MEDLINE: Immunotherapy, Tertiary Lymphoid Structures, Biocompatible Materials, Hydrogels. Die Arbeit nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tsinghua-Toyota Joint Research Fund.
Abstract (Originalsprache)
Tumor-associated tertiary lymphoid structures (TLSs) can promote anti-tumor immune responses and survival. However, intratumor TLS formation and maturation are limited in tumors with a “cold” immune phenotype, including reduced infiltration of immune cells and a suppressive tumor microenvironment (TME). Here, we present a personalized immunotherapy strategy utilizing a subcutaneously injected, bioengineered hydrogel (scTLS) that acts as an ectopic immune-activation center, effectively decoupled from the suppressive TME. Native immune cells and antigen-presenting cells (APCs) with autologous antigens are recruited through the release of chemokines. An agonist for CD40 is modified on the gel, enabling an immune-activated environment. We demonstrate that scTLSs promote robust dendritic cell (DC) activation and antigen presentation, driving the formation of organized T and B cell zones as confirmed by 3D imaging and transcriptomic analysis. This personalized, autologous vaccine-based approach elicited potent anti-tumor immune responses and effectively inhibited tumor progression across multiple murine models, with enhanced efficacy upon combination with doxorubicin-induced immunogenic cell death and immune checkpoint blockade. By overcoming the spatial and immunosuppressive limitations of the native TME, our scTLS platform offers a versatile, "off-the-shelf" engineering strategy for inducing functional TLSs to enhance therapeutic outcomes in a broad spectrum of malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology (Ministry of Education), Department of Chemistry, Tsinghua University, Beijing100084, China.
- Center for Synthetic and Systems Biology, Tsinghua University, Beijing100084, China.
ORCID-Profile: Yan-Mei Li
Förderung
- National Natural Science Foundation of China
- Tsinghua-Toyota Joint Research Fund
Zitieren
APA
Su, J. Y., Wang, T. Y., Zhuo, S. H., Feng, G. H., & Li, Y. M. (2026). Engineering Subcutaneous Ectopic Tertiary Lymphoid Structures as Personalized Immune-Activation Niches for Cancer Immunotherapy. ACS Applied Bio Materials, 9(21), 10525-10535. https://doi.org/10.1021/acsabm.6c01731
Vancouver
Su JY, Wang TY, Zhuo SH, Feng GH, Li YM. Engineering Subcutaneous Ectopic Tertiary Lymphoid Structures as Personalized Immune-Activation Niches for Cancer Immunotherapy. ACS Applied Bio Materials. 2026;9(21):10525-10535. doi:10.1021/acsabm.6c01731
BibTeX
@article{Su2026,
author = {Su, Jing-Yun and Wang, Tian-Yang and Zhuo, Shao-Hua and Feng, Geng-Hui and Li, Yan-Mei},
title = {Engineering Subcutaneous Ectopic Tertiary Lymphoid Structures as Personalized Immune-Activation Niches for Cancer Immunotherapy},
journal = {ACS Applied Bio Materials},
year = {2026},
volume = {9},
number = {21},
pages = {10525--10535},
doi = {10.1021/acsabm.6c01731}
}
EUVIMED